Celgene CEO Dr. Sol J. Barer to Appear Live on ''Corporate Strategies with Tim Connolly'' Sunday, July 2, 2006 at 9:00 p.m. EST.

HOUSTON -- Please replace the release with the following corrected version due to multiple revisions.

The corrected release reads:

CELGENE CEO DR. SOL J. BARER TO APPEAR LIVE ON "CORPORATE STRATEGIES WITH TIM CONNOLLY" SUNDAY, JULY 2, 2006 AT 9:00 P.M. EST

Dr. Barer will discuss expected approval of REVLIMID (lenalidomide) for the treatment of patients with Multiple Myeloma 

Celgene (Nasdaq:CELG) CEO Dr. Sol J. Barer will appear live on "Corporate Strategies with Tim Connolly", Sunday, July 2, 2006 at 9:00 p.m. EST. Dr. Barer will discuss the FDA's expected approval of REVLIMID (lenalidomide) for the treatment of patients with Multiple Myeloma and how Celgene has become the leader in global biotechnology targeting the discovery, development and commercialization of pharmaceuticals for the treatment of serious and debilitating diseases. Emerge Capital Corp. (OTCBB:EMGC) is the lead sponsor of The Corporate Strategies Business Talk Radio Show which may be heard on KSEV AM 700 in Houston, Texas, WGCH AM 1490 in Greenwich, Connecticut, WSBR AM 740 in Boca Raton, Florida, KBNP AM 1410 in Portland, Oregon, and on over 400 affiliate stations nationwide listed at CRN1 www.cableradionetwork.com, or on the Internet at www.businesstalkradio.net. Listeners may call in live and toll free at 1-866-606-TALK (8255) to speak with Dr. Barer or Tim. Previous guests of the show have included US Senator John McCain, ChangeWave Research's Bryan Perry, Enterprise Products CEO Dan Duncan, Landry's CEO Tilman Fertitta, Ben & Jerry's Ice Cream Cofounder Ben Cohen, Mario Gabelli, former SEC Chairman Arthur Levitt, former Compaq CEO Eckard Pfeiffer, Money Manager Louis Navellier, and many others. This hour of "Corporate Strategies with Tim Connolly" is hosted by Tim Connolly of Corporate Strategies Merchant Bankers (www.corporate-strategies.net). Noted Economist Mike King of Princeton Research provides live technical analysis for the show.

About Emerge Capital Corp and Corporate Strategies, Inc. - Emerge Capital Corp. (OTCBB:EMGC) provides business growth, organizational restructuring, and turnaround execution services for emerging and re-emerging public companies through our wholly owned subsidiary, Corporate Strategies, Inc. (www.corporate-strategies.net). Emerge Capital is unique because we accept payment for our services in the common stock of the companies we serve, aligning our interests with those of the client's shareholders and preserving their corporate cash reserves for working capital and growth. As Emerge Capital succeeds, the shareholders of our valued clients succeed. Emerge Capital believes our approach provides Emerge shareholders with an opportunity to realize greater gains than merely receiving cash payments for our services. We consider Emerge Capital to be the ultimate business resource for emerging and re-emerging public companies.

About Celgene - Celgene is a multinational integrated biopharmaceutical company, incorporated in 1986 as a Delaware corporation. As a leader in global biotechnology, Celgene has built an integrated discovery, development and commercialization platform for drug and cell-based therapies that enables the company to continue to develop value within its therapeutic franchise areas of cancer and inflammatory diseases. At the center of Celgene's opportunities are people, patients, partners, providers and product pipeline - all of which add up to One Company, One Celgene making potentially life-saving new treatments a reality.

All statements included in this press release, other than statements of historical fact, are forward-looking statements. Although Management believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Important factors could cause actual results to differ materially from the expectations that are disclosed in this Press Release. While Emerge Capital Corp/Corporate Strategies, Inc. believes its forecasting assumptions are reasonable, there are factors that are hard to predict and influenced by economic and other conditions that are beyond Emerge Capital Corp/Corporate Strategies, Inc.'s control. Among the other important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in Emerge Capital Corp/Corporate Strategies, Inc.'s filings with the Securities and Exchange Commission.